Washington Trust’s Genmab GMAB Stock Holding History

Washington Trust’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-109	Closed	-$2K	–	914
2020 Q1	$2K	Buy	+109	New	+$2.43K	﹤0.01%	832

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Washington Trust's GMAB Position: Q2 2020 in Review

Washington Trust sold out of Genmab (GMAB) in Q2 2020, closing a stake of 109 shares — an estimated $2K sold.

Washington Trust first reported a position in GMAB in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 174 funds tracked by Wall St. Rank hold GMAB as of Q2 2020.

Washington Trust reported no remaining Genmab position as of Q2 2020 after selling out during the quarter.
Washington Trust sold 109 Genmab shares in Q2 2020, an estimated $2K.
Washington Trust first reported a position in Genmab in Q1 2020 and held it in 1 quarter.
Washington Trust's Genmab position peaked at $2K in Q1 2020.
174 funds tracked by Wall St. Rank held Genmab as of Q2 2020.

Based on Washington Trust's 13F filing for Q2 2020, filed 4 Aug 2020.